SCHEMBL24077389

SCHEMBL24077389

CC(=O)c1n[nH]c(=O)c2ccc(C(F)(F)F)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.44
▸ AURKB Q96GD4 2/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KIF11 P52732 1/20 0.43
▸ GSK3B P49841 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ MAP2K4 P45985 4/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ MAPK6 Q16659 3/20 0.41
▸ MAPKAPK3 Q16644 2/20 0.41
▸ MAPKAPK5 Q8IW41 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ROCK1 Q13464 1/20 0.40
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ PDE2A O00408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076861 0.87 PDE2A (0.44) AURKBKMT2AMEN1USP2HSD17B10
SCHEMBL24076884 0.78 MEN1 (0.47) AURKBKMT2AMEN1MAPTKIF11
SCHEMBL30168572 0.78 MEN1 (0.47) AURKBKMT2AMEN1MAPTKIF11
SCHEMBL24077092 0.78 POLB (0.47) KMT2AMEN1USP2HSD17B10MAPT
SCHEMBL24076276 0.77 MAPT (0.36) AURKBKMT2AMEN1USP2HSD17B10
SCHEMBL24076862 0.76 MAPT (0.47) AURKBHSD17B10MAPTGSK3BPARP1
SCHEMBL24076899 0.75 MAPT (0.53) MAPTGSK3BPARP1SMN1; SMN2PRMT5
SCHEMBL24076896 0.75 MAPT (0.44) AURKBHSD17B10MAPTGSK3BPARP1
SCHEMBL29426569 0.75 MAPT (0.44) AURKBHSD17B10MAPTGSK3BPARP1
SCHEMBL30319377 0.75 KMT2A (0.38) KMT2AMEN1PARP1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
EP-4157823-A1 COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-04-05 — — EP disclosed
CN-115667225-A Compound (I) 詹森药业有限公司 2023-01-31 — — CN disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B ATM 4307/4885AURKB 1393/4885KMT2A 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback